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SUMMARY
With the growing incidence of diabetes mellitus (DM), an increasing num-
ber of organ donors with DM can be expected. We sought to investigate
the association between donor DM with early post-transplant outcomes.
From a national cohort of adult liver transplant recipients (1996–2016), all
recipients transplanted with a liver from a DM donor (n = 69) were
matched 1:2 with recipients of livers from non-DM donors (n = 138). The
primary end-point included early post-transplant outcome, such as the
incidence of primary nonfunction (PNF), hepatic artery thrombosis
(HAT), and 90-day graft survival. Cox regression analysis was used to ana-
lyze the impact of donor DM on graft failure. PNF was observed in 5.8%
of grafts from DM donors versus 2.9% of non-DM donor grafts
(P = 0.31). Recipients of grafts derived from DM donors had a higher
incidence of HAT (8.7% vs. 2.2%, P = 0.03) and decreased 90-day graft
survival (88.4% [70.9–91.1] vs. 96.4% [89.6–97.8], P = 0.03) compared to
recipients of grafts from non-DM donors. The adjusted hazard ratio for
donor DM on graft survival was 2.21 (1.08–4.53, P = 0.03). In conclusion,
donor DM is associated with diminished outcome early after liver trans-
plantation. The increased incidence of HAT after transplantation of livers
from DM donors requires further research.
Transplant International 2020;
Key words
diabetes mellitus, donor diabetes, hepatic artery thrombosis, liver transplantation, outcome,
postoperative complications
Received: 24 May 2020; Revision requested: 9 July 2020; Accepted: 11 October 2020
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT 1
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,




The ongoing gap between the supply of and demand for
donor livers available for transplantation has led to an
increase in the use of extended criteria donor (ECD)
livers. Conventional ECD parameters include donors
with higher age, abnormal liver function tests, hyperna-
tremia, hepatic steatosis, prolonged intensive care unit
stay, use of vasopressors, resuscitation, and donors posi-
tive for viral hepatitis B or C. Donation after circulatory
death, or donors with comorbidities, such as hyperten-
sion or diabetes mellitus (DM) are considered addi-
tional risk factors [1].
Globally, the number of people with DM has more
than doubled over the past two decades. In the Uni-
ted States, 23.7 million adults were diagnosed with
DM in 2011 and this number is expected to increase
to 29.6 million in 2030, making up 11.8% of the
national population [2]. In the Netherlands, 8.8% of
the national population is expected to to be living
with DM by 2030 [3]. Consequently, an increasing
number of potential deceased organ donors is likely
to have DM.
DM is associated with nonalcoholic fatty liver disease
(NAFLD) [4], which is a spectrum of diseases ranging
from hepatic steatosis to nonalcoholic steatohepatitis
(NASH) and cirrhosis [5,6]. In addition, DM has been
associated with an impaired liver microvascular circula-
tion, making these grafts more vulnerable to ischemic
injury sustained during transplantation [7].
Studies on the use of liver grafts derived from
donors with DM have not yet been performed in Euro-
pean cohorts, and there are currently no published data
on early postoperative complications, such as primary
nonfunction (PNF) and hepatic artery thrombosis
(HAT) after liver transplantation using grafts from DM
donors [8–10]. Also, there are no studies comparing
outcome after transplantation of livers from donors
with type 1 (DM1) versus type 2 DM (DM2). The
pathophysiology of DM1 versus DM2 is different, with
the latter being more often associated with the meta-
bolic syndrome and NAFLD [4,11,12]. We, therefore,
hypothesized that outcome after transplantation of liv-
ers from DM2 donors would be inferior to that of liv-
ers from DM1 donors.
We conducted a national multicenter study to exam-
ine early postoperative outcome after transplantation
with liver grafts from DM donors compared to non-




We performed a retrospective cohort study including
all consecutive patients who underwent liver trans-
plantation with a graft derived from a donor with
DM between January 1, 1996, and December 31,
2016, in the Netherlands. Exclusion criteria included
recipient age < 18 years, split liver grafts, and com-
bined organ transplantation. Donor characteristics
were obtained from Eurotransplant. A donor was con-
sidered to be diabetic when the box “diabetes melli-
tus” in the Eurotransplant database was ticked “yes,”
or if it was explicitly stated in the box “other com-
ments.” A distinction between DM1 versus DM2 was
made based on the specific description “type 1” or
“type 2” next to the box “diabetes mellitus” in the
Eurotransplant database or in the box “other com-
ments.” A graft was considered “steatotic” if the radi-
ology report specifically stated “hepatic steatosis” or if
the “steatosis” box in the NTS quality form was
ticked “yes.” Recipient characteristics and surgical
variables were derived from prospectively maintained
databases in each participating center. Post-transplan-
tation laboratory data were obtained from chart
review. The study was approved by the Institutional
Review Board of the University Medical Center
Groningen (202000250) and adhered to the Declara-
tion of Helsinki and the Declaration of Istanbul. The
study was performed consistent with STROBE
(Strengthening the Reporting of Observational studies
in Epidemiology) guidelines.
To examine the effect of donor DM on outcome
after liver transplantation, all recipients receiving a
graft from a DM donor were individually matched at
random with two recipients who received a liver from
a non-DM donor. To eliminate any confounding by a
“center effect,” the matching process was stratified per
transplant center. Matching was based on the follow-
ing variables: year of transplantation (2 years),
whether it was a retransplantation, and the balance of
risks (BAR) score (2 points). The BAR score pre-
dicts post-transplant survival, and the formula is
based on the Model for End-stage Liver Disease
(MELD) score, retransplantation, whether the patient
was receiving life support prior to the transplantation,
recipient age, cold ischemia time (CIT), and donor
age [13]. The BAR score was calculated on the day of
liver transplantation.
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Outcome parameters
Early post-transplant outcome was considered the pri-
mary outcome of this study. PNF was defined as non-
life-sustaining liver function requiring retransplantation
or leading to death within 7 days after transplantation.
HAT was defined as a radiologically or surgically pro-
ven thrombosis of the hepatic artery. Graft loss was
defined as the time between transplantation and death
related to graft failure or retransplantation. Patients
that died with a functioning graft were censored in the
graft survival analysis. Patient survival was defined as
the time interval between transplantation and all-cause
mortality. Late post-transplant outcome was evaluated
as a secondary outcome. Nonanastomotic biliary stric-
tures (NAS) were defined as any stricture of the donor
bile duct except those localized near the biliary anasto-
mosis and in the absence of HAT. Outcomes were
analyzed by type of donor DM. Follow-up was
recorded up to 3 years after baseline, or until Decem-
ber 31, 2017.
Statistical analysis
Categorical variables were presented as numbers and
percentages. Continuous variables were presented as
median and interquartile range. Comparisons between
the groups were made using chi-square test for cate-
gorical variables and Mann–Whitney U test for con-
tinuous variables. Unadjusted 3-year Kaplan–Meier
survival curves were used to graphically depict graft
and patient survival stratified by donor DM status,
and differences between the groups were evaluated
using the log-rank test. Cox proportional-hazards
regression modeling was used to assess the effect of
donor DM on 3-year graft survival after adjustment
for relevant factors selected by backward elimination
techniques. The following variables were analyzed in
the first step of the backward elimination process
after careful selection based on literature and back-
ground knowledge [9,10,13,14]: donor DM, recipient
age, MELD score, and whether it was a retransplanta-
tion. Risk related to graft failure was expressed as
hazard ratio (HR) with 95% confidence interval (CI).
Analyses by a Cox proportional-hazards model was
chosen, because matching was performed by using the
entire database of non-DM donors in the Netherlands
(n = 2,616) to search, at random, for the nearest (by
date of transplantation) potential match by BAR score
and retransplantation rendering the risk of within-
cluster homogeneity as low.
A P-value of 0.05 or less was considered significant.
All analyses were conducted using the statistical soft-
ware SPSS version 23.0 (SPSS Inc., Chicago, IL, USA).
Results
Donor diabetes
During the study period, 2,351 adult patients received a
deceased donor liver, of whom 69 (2.9%) received a
graft derived from a donor with DM. The proportion of
liver donors with DM has increased over the years
(Fig. 1). Recipients of DM donor livers were matched
to a control group consisting of 138 recipients of non-
DM donor livers, adding up to a total of 207 recipients
included in this study. The median follow-up time was
49 (18–71) months in the DM donor group and 43
(24–57) months in the non-DM donor group. Of DM
donors, 19 (27.5%) had DM1 and 41 (59.4%) had
DM2. Data on type of DM were missing for 9 cases
(13.0%). These 9 missing cases were excluded for sub-
analysis on the influence of type of donor DM.
Donor and recipient characteristics
There were no significant differences between recipients
of the study group and the matched control group. DM
donors had a slightly higher body mass index (BMI)
compared to non-DM donors (26 (24–29) vs. 25 (23–
27), P = 0.02) and were more likely to suffer from
hypertension compared to non-DM donors (58.5% vs.
26.4%, P < 0.01) (Table 1). Although DM donors
Figure 1 Percentage of donors with diabetes between 1996 and
2016 in the Netherlands. Data on total number of liver donors were
obtained from the Dutch Transplant Society [28]. The bars represent
the percentage of donors with DM of the total number of liver
donors in the corresponding year.
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tended to more often die from anoxia (17.4% vs. 8.7%,
P = 0.07) and to have alcohol abuse (19.6% vs. 9.6%,
P = 0.07), these differences did not reach statistical sig-
nificance. The percentage of steatotic grafts was not dif-
ferent between DM versus non-DM donors (19.1% vs.
18.6%, P = 0.95), but data were only available for 106/
207 donors. Cold and warm ischemia times were not
different between the study group and the control
group.
Early post-transplant outcomes
PNF was observed in 5.8% of grafts derived from DM
donor grafts, compared to 2.9% of non-DM donor
grafts (P = 0.31) (Table 2). Grafts derived from a donor
with a history of DM were significantly more often
complicated with HAT after liver transplantation (8.7%
vs. 2.2%, P = 0.03). Recipients of livers from DM
donors had lower 90-day graft (88.4% [70.9–91.1] vs.
96.4% [89.6–97.8], P = 0.03) and patient (92.8% [86.9–
95.6] vs. 97.1% [93.3–99.3], P = 0.31) survival com-
pared to recipients of livers from non-DM donors, but
the difference was only significant for graft survival.
Late post-transplant outcomes
The incidence of NAS was nonsignificantly lower in the
DM donor group (14.5% vs. 21.4%, P = 0.26). Three-
year graft (78.3% [66.6–86.3] vs. 89.1% [82.6–93.3],
P = 0.03) and patient (84.0% [73.0–91.3] vs. 95.7%
[90.5–98.0], P = 0.01) survival were significantly lower
for recipients receiving a liver graft from a DM donor
compared to those who received a graft from a non-
DM donor (Fig. 2).






(n = 138) P-value*
Recipient variable
Age (years) 54 (45–60) 54 (45–59) 54 (45–60) 0.89
Female, % (n) 32.4% (67) 40.6% (28) 28.3% (39) 0.08
BMI (kg/m2) 25 (23–29) 25 (23–29) 25 (23–29) 0.51
BAR score 7 (3–12) 7 (3–12) 7 (3–12) 0.70
Laboratory MELD score 18 (12–25) 19 (12–28) 18 (13–25) 0.56
Retransplantation, % (n) 17.4% (36) 17.4% (12) 17.4% (24) >0.99
HCV, % (n) 14.5% (30) 15.9% (11) 13.8% (19) 0.68
NASH, % (n) 8.7% (18) 8.7% (6) 8.7% (12) >0.99
Donor variables
Age (years) 57 (46–64) 59 (49–65) 56 (43–64) 0.08
Female, % (n) 42.5% (88) 45.3% (31) 44.0% (61) 0.87
BMI (kg/m2) 25 (23–28) 26 (24–29) 25 (23–27) 0.02
DCD, % (n) 18.4% (38) 15.9% (11) 19.6% (27) 0.53
Cause of donor death, % (n)
CVA 66.7% (138) 62.3% (43) 68.8% (95) 0.33
Trauma 14.5% (30) 13.0% (9) 15.2% (21) 0.65
Anoxia 11.6% (24) 17.4% (12) 8.7% (12) 0.07
Other 7.2% (15) 7.3% (5) 7.3% (10) 0.66
Comorbidities, % (n)
Hypertension 36.8% (76) 58.5% (40) 26.4% (36) <0.01
Smoking 61.5% (127) 67.8% (47) 58.4% (81) 0.24
Alcohol 12.9% (27) 19.6% (14) 9.6% (13) 0.07
Hepatic steatosis, % (n) 18.9% (20#) 19.1% (9#) 18.6% (11) 0.95
Surgical variables
CIT (min) 402 (340–478) 386 (332–454) 415 (341–483) 0.31
WIT (min) 34 (28–40) 34 (29–43) 35 (28–40) 0.39
BAR, balance of risks; BMI, body mass index; CIT, cold ischemia time; CVA, cerebrovascular accident; DCD, donation after cir-
culatory death; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; NASH, nonalcoholic steatohepatitis;
WIT, warm ischemia time. Numbers are expressed as percentages (number) or median (interquartile range).
*P-value is based on columns diabetic donor versus nondiabetic donor. A P-value < 0.05 was considered significant. # there
were missing data for this variable.
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According to the Cox model, donor DM was associ-
ated with a higher 3-year risk of graft loss compared to
donors without DM with a HR of 2.15 (1.05–4.40,
P = 0.04). After adjusting for the risk factors in multi-
variable analyses (recipient age, MELD score and
retransplantation), donor DM remained associated with
a higher risk of graft loss with an adjusted hazard ratio
of 2.21 (1.08–4.53, P = 0.03) (Table 3).
Donor diabetes type 1 versus type 2
Donors with DM2 were older (61 (55–67) vs. 49 (43–
60), P < 0.01), had a higher BMI (26 (25–29) vs. 24
(22–27), P = 0.04), and had more often died from a
cerebrovascular accident (73.2% vs. 36.8%, P = 0.01),
compared to DM1 donors. Of the data available, 0/12
(0.0%) grafts were steatotic in the DM1 group, whereas
6/30 (20.0%) grafts from DM2 donors had steatosis
(P = 0.09) (Table S1).
There were no significant differences in early post-
transplant outcomes between recipients of livers from
donors with DM1 versus DM2 (Table 4). Ninety-day
graft and patient survival were 84.2% [58.7–94.6] and
94.7% [79.0–97.6] in the DM1 group and 92.7% [68.1–
99.2] and 92.7% [79.0–97.6] in the DM2 group, respec-
tively. The incidence of NAS was almost two times higher
in livers from DM1 donors, compared to DM2 donors,
but this difference did not reach statistical significance
Figure 2 Graft and patient survival after liver transplantation of grafts from nondiabetic donors versus diabetic donors. Unadjusted Kaplan–
Meier survival curves are shown for 3-year graft and patient survival. Comparisons between the groups were made using the log-rank test.
Dotted line represents 95% confidence interval. Abbreviations: DM, diabetes mellitus.
Table 2. Post-transplant outcomes after liver transplantation with grafts from diabetic versus nondiabetic donors
Variable
Diabetic donor
(n = 69) 95% CI
Nondiabetic donor
(n = 138) 95% CI P-value
Early post-transplant outcomes
PNF 5.8% (4) 1.6–14.2 2.9% (4) 0.8–7.3 0.31
HAT 8.7% (6) 3.3–18.0 2.2% (3) 0.5–6.2 0.03
90-day graft survival 88.4% (61) 70.9–91.1 96.4% (133) 89.6–97.8 0.03
90-day patient survival 92.8% (64) 86.9–95.6 97.1% (134) 93.3–99.3 0.31
Late post-transplant outcomes
NAS 14.5% (10) 7.2–25.0 21.0% (29) 13.9–30.5 0.26
3-year graft survival 78.3% (54) 66.6–86.3 89.1% (123) 82.6–93.3 0.03
3-year patient survival 84.0% (58) 73.0–91.3 95.7% (133) 90.5–98.0 0.01
CI, confidence interval; HAT, hepatic artery thrombosis; PNF, primary nonfunction; NAS, nonanastomotic biliary strictures.
Numbers are expressed as percentages (number). Outcomes were compared using the chi-square test. A P-value < 0.05 was
considered significant.
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(21.1% vs. 12.2%, P = 0.37). Three-year graft and patient
survival were 78.9% [53.2–91.5] and 84.2% [62.1–87.9]
in the DM1 group and 78.0% [58.7–94.6] and 87.5%
[72.5–94.6] in the DM2 group, respectively.
Discussion
The growing incidence of DM is a worldwide phe-
nomenon, and it is therefore not unlikely that the num-
ber of organ donors with a history of DM will increase
in the near future. In this national multicenter study,
we found inferior early post-transplant outcomes for
recipients of liver grafts from DM donors compared to
non-DM donors.
Several studies have reported on outcomes associated
with recipient DM at the time of liver transplantation,
and it was generally found that recipient DM is associ-
ated with inferior outcome [15–18]. Only few studies
analyzed the effect of donor DM on outcome following
liver transplantation [8–10]. In accordance with previ-
ous studies, we found reduced graft and patient survival
for recipients of livers from DM donors, compared to
non-DM donors [9,10]. It is worth mentioning that
there are notable differences in donor characteristics
between our study performed in a European cohort ver-
sus previous studies in American cohorts [9,10]. For
example, the DM donors in this study had a lower BMI
(26 versus 30) and less often suffered from additional
hypertension (60% vs. 75–80%) compared to DM
donors in studies using American data registries [8,9].
As a novel finding, this study showed a higher inci-
dence of HAT after transplantation using livers from
donors with DM. In the literature, DM has been associ-
ated with an impaired liver microvascular circulation,
making these grafts more vulnerable to ischemic injury,
and potentially increasing the risk of vascular complica-
tions after liver transplantation [7,19,20]. Previous
reports on liver transplant recipients with DM have sug-
gested an increased prevalence of vascular complications
after transplantation [21,22]. Also, higher rates of late
onset HAT have been described in transplant recipients
with new-onset DM after transplantation [23]. As sug-
gested by Fiel et al., identification of histological mark-
ers of DM-related liver injury, such as vascular wall
Table 3. Multivariable Cox proportional-hazards
regression model for graft survival after liver
transplantation
Variable HR 95% CI P-value
Recipient
Age 0.96 0.94–0.99 <0.01
Donor
Diabetes 2.21 1.08–4.53 0.03
CI, confidence interval; HR, hazard ratio; MELD, model for
end-stage liver disease.
Graft survival was defined as death-censored graft failure or
retransplantation. The multivariable model was conducted via
a backwards stepwise approach. The following variables were
analyzed in the first step of the multivariable model: donor
diabetes, recipient age, recipient MELD score, and whether it
was a retransplantation. A P-value < 0.05 was considered
significant.
Table 4. Post-transplant outcomes after liver transplantation with grafts from donors with diabetes type 1 versus type 2
Variable
Donor DM type 1
(n = 19) 95% CI
Donor DM type 2
(n = 41) 95% CI P-value
Early post-transplant outcomes
PNF 5.2% (1) 0.1–26.0 4.9% (2) 0.6–16.5 0.94
HAT 10.5% (2) 1.3–33.1 9.8% (4) 2.7–23.1 0.57
90-day graft survival 84.2% (16) 58.7–94.6 92.7% (38) 68.1–99.2 0.31
90-day patient survival 94.7% (18) 79.0–97.6 92.7% (38) 79.0–97.6 0.77
Late post-transplant outcomes
NAS 21.1% (4) 6.1–45.6 12.2% (5) 4.1–26.2 0.37
3-year graft survival 78.9% (15) 53.2–91.5 78.0% (32) 58.7–94.6 0.94
3-year patient survival 84.2 (16) 62.1–87.9 87.5 (35) 72.5–94.6 0.73
CI, confidence interval; DM, diabetes mellitus; HAT, hepatic artery thrombosis; PNF, primary nonfunction; NAS, nonanasto-
motic biliary strictures.
Numbers are expressed as percentages (number). Outcomes were compared using the chi-square test. A P-value < 0.05 was
considered significant.
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thickness, and their correlation with worse outcome
after transplantation could be of interest for future
research [24]. If larger cohort studies confirm an
increased risk of vascular complications in DM donor
grafts, more targeted therapy or diagnostics may be
used to prevent thrombosis in these livers. Graft steato-
sis may have an impact on outcome after transplanta-
tion using grafts from DM donors. Unfortunately, a
high number of missing data hampered thorough analy-
sis on the influence of donor graft steatosis. Of the data
available, the percentage of grafts with steatosis among
DM versus non-DM donors was similar. Moreover, DM
donors only had a slightly higher BMI, which has previ-
ously been used as a surrogate marker for hepatic
steatosis by others [10,25,26]. We, therefore, suggest
that microvascular changes in DM donor grafts rather
than the amount of steatosis contribute to diminished
outcome after transplantation, but this remains specula-
tive.
To the best of our knowledge, this is the first study
describing the effect of type 1 versus type 2 donor DM.
The incidence of NAS was almost two times higher in
livers from DM1 donors, compared to DM2 donors,
but these differences did not reach statistical signifi-
cance. Yet, this study was not powered to detect differ-
ences between type of donor DM and confirmation of
these observations should follow from studies in larger
cohorts. Noteworthy, DM2 has an etiological role in
NAFLD, which could progress to cirrhosis and hepato-
cellular carcinoma [27], but donor livers with signs of
fibrosis or cirrhosis will not be accepted for transplanta-
tion suggesting that only selected DM2 livers were
included in this study.
Although the present study provides new information
on the impact of donor DM on liver transplantation
outcomes, it has some limitations, such as the relatively
small sample size. As such, we were only able to analyze
a small number of variables in our multivariable model.
We acknowledge that the influence of donor graft
steatosis, the duration of donor DM, and type of DM
medication can be of interest, but these variables could
not be analyzed as they are scarcely reported in the
Eurotransplant donor database. The influence of incom-
plete data and the accuracy of the data registry are
recurrent limitations of registry database studies, carry-
ing an inherent bias.
In conclusion, donor DM is a risk factor for dimin-
ished outcome in the early postoperative period after
liver transplantation. The increased incidence of HAT
after transplantation of livers from DM donors requires
further research.
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